Infections in patients with rheumatic diseases treated with TNF antagonists

Current Pharmaceutical Biotechnology

Volumn 13, Issue 8, 2012, Pages 1418-1425

  Pérez Zafrilla, Beatriz ^a   Carmona, Loreto ^b   Gómez Reino, Juan J ^c  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b UNIDAD DE INVESTIGACIÓN   (Spain)

^c University Hospital of Santiago de Compostela   (Spain)

Author keywords

"Adalimumab" Substance Name ; "Ankylosing spondylitis" Mesh ; "Etanercept" Substance name ; "Infections" mesh ; "Infliximab" Substance name ; "Rheumatic diseases" Mesh ; "Safety" Mesh ; "Tumor necrosis factor antagonist" Mesh

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE;

ANKYLOSING SPONDYLITIS; APPENDICITIS; ARTICLE; ASEPTIC MENINGITIS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BRONCHITIS; BRONCHOPNEUMONIA; BRUCELLA MELITENSIS; CANDIDA ALBICANS; CANDIDIASIS; DIABETES MELLITUS; ETHNICITY; FLU LIKE SYNDROME; GASTROINTESTINAL INFECTION; GERMANY; GRANULOMATOUS INFECTION; HERPES SIMPLEX; HERPES ZOSTER; HISTOPLASMOSIS; HISTOPLASTOMA CAPSULATUM INFECTION; HUMAN; IMMUNE RESPONSE; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LISTERIA MONOCYTOGENES; LISTERIOSIS; MEDLINE; MYCOBACTERIUM TUBERCULOSIS; MYCOSIS; PERITONITIS; PHARYNGITIS; PNEUMONIA; PSORIATIC ARTHRITIS; PYELONEPHRITIS; RHEUMATOID ARTHRITIS; RHINITIS; SALMONELLA; SEPSIS; SINUSITIS; SMOKING; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; SWEDEN; SYSTEMATIC REVIEW; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; UNITED KINGDOM; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VIRUS REACTIVATION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; HUMANS; OPPORTUNISTIC INFECTIONS; RHEUMATIC FEVER; TUMOR NECROSIS FACTORS;

EID: 84862610971     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800784808     Document Type: Article

References (91)

1. Deepe, G.S., Jr.; Smelt, S.; Louie, J.S., Tumor necrosis factor inhibition and opportunistic infections. Clin. Infect. Dis., 2005, 41(Suppl 3), S187-188.
2. Feldmann, M.; Maini, R.N., Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol., 2001, 19, 163-196.
3. Kindler, V.; Sappino, A.P.; Grau, G.E.; Piguet, P.F.; Vassalli, P., The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell, 1989, 56(5), 731-740.
4. Locksley, R.M.; Killeen, N.; Lenardo, M.J., The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell., 2001, 104(4), 487-501.
5. Roach, D.R.; Bean, A.G.; Demangel, C.; France, M.P.; Briscoe, H.; Britton, W. J., TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol., 2002, 168(9), 4620-4627.
6. Cunnane, G.; Doran, M.; Bresnihan, B. Infections and biological therapy in rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol., 2003, 17(2), 345-363.
7. Benoit, S.; Toksoy, A.; Brocker, E. B.; Gillitzer, R.; Goebeler, M. Treatment of recalcitrant pustular psoriasis with infliximab: effecttive reduction of chemokine expression. Br. J. Dermatol., 2004, 150(5), 1009-1012.
8. Paleolog, E.M.; Hunt, M.; Elliott, M.J.; Feldmann, M.; Maini, R.N.; Woody, J. N., Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum, 1996, 39(7), 1082-1091.
9. Tak, P.P.; Taylor, P.C.; Breedveld, F.C.; Smeets, T.J.; Daha, M.R.; Kluin, P.M.; Meinders, A.E.; Maini, R.N., Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum., 1996, 39(7), 1077-1081.
10. Beresford, M.W.; Baildam, E.M. New advances in the management of juvenile idiopathic arthritis--2: the era of biologicals. Arch. Dis. Child Educ. Pract. Ed., 2009, 94(5), 151-156.
11. Braun, J.; Sieper, J., Biological therapies in the spondyloarthritides-the current state. Rheumatology, (Oxford), 2004, 43(9), 1072-1084.
12. Olsen, N.J.; Stein, C.M., New drugs for rheumatoid arthritis. N. Engl. J. Med., 2004, 350(21), 2167-2179.
13. Wallis, R.S.; Broder, M.; Wong, J.; Lee, A.; Hoq, L., Reactivation of latent granulomatous infections by infliximab. Clin. Infect. Dis., 2005, 41(Suppl 3), S194-S198.
14. Doran, M.; Crowson, C.; Pond, G.; O'Fallon, W.; Gabriel, S. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum., 2002, 46(9), 2287-2293.
15. Franklin, J.; Lunt, M.; Bunn, D.; Symmons, D.; Silman, A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann. Rheum. Dis., 2007, 66(3), 308-312.
16. Smitten, A.; Choi, H.; Hochberg, M.; Suissa, S.; Simon, T.; Testa, M.; Chan, K., The risk of hospitalized infection in patients with rheumatoid arthritis. J. Rheumatol., 2008, 35(3), 387-393.
17. Doran, M.F.; Crowson, C.S.; Pond, G.R.; O'Fallon, W.M.; Gabriel, S.E., Predictors of infection in rheumatoid arthritis. Arthritis Rheum., 2002, 46(9), 2294-2300.
18. Breedveld, F.C.; Weisman, M.H.; Kavanaugh, A.F.; Cohen, S.B.; Pavelka, K.; van Vollenhoven, R.; Sharp, J.; Perez, J.L.; Spencer-Green, G.T., The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum., 2006, 54(1), 26-37.
19. St Clair, E. W.; van der Heijde, D.M.; Smolen, J.S.; Maini, R.N.; Bathon, J.M.; Emery, P.; Keystone, E.; Schiff, M.; Kalden, J.R.; Wang, B.; Dewoody, K.; Weiss, R.; Baker, D. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum., 2004, 50(11), 3432-3443.
20. Bongartz, T.; Sutton, A.J.; Sweeting, M.J.; Buchan, I.; Matteson, E.L.; Montori, V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA., 2006, 295(19), 2275-2285.
21. Listing, J.; Strangfeld, A.; Kary, S.; Rau, R.; von Hinueber, U.; Stoyanova-Scholz, M.; Gromnica-Ihle, E.; Antoni, C.; Herzer, P.; Kekow, J.; Schneider, M.; Zink, A. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum., 2005, 52(11), 3403-3412.
22. Askling, J.; Fored, C.M.; Brandt, L.; Baecklund, E.; Bertilsson, L.; Feltelius, N.; Coster, L.; Geborek, P.; Jacobsson, L.T.; Lindblad, S.; Lysholm, J.; Rantapaa-Dahlqvist, S.; Saxne, T.; van Vollenhoven, R.F.; Klareskog, L. Time-dependent increase in risk of hospitalization with infection among Swedish RA patients treated with TNF antagonists. Ann. Rheum. Dis., 2007, 66(10), 1339-1344.
23. Crum, N.F.; Lederman, E.R.; Wallace, M.R., Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore), 2005, 84, (5), 291-302.
24. Curtis, J.R.; Patkar, N.M.; Jain, A.; Greenberg, J.; Solomon, D.H., Validity of physician-reported hospitalized infections in a US arthritis registry. Rheumatology (Oxford), 2009, 48(10), 1269-1272.
25. Dixon, W.; Watson, K.; Lunt, M.; Hyrich, K.; Silman, A.; Symmons, D., Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum., 2006, 54(8), 2368-2376.
26. Hamilton, C.D. Infectious complications of treatment with biologic agents. Curr. Opin. Rheumatol., 2004, 16(4), 393-398.
27. Schneeweiss, S.; Setoguchi, S.; Weinblatt, M.E.; Katz, J.N.; Avorn, J.; Sax, P.E.; Levin, R.; Solomon, D.H. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum., 2007, 56(6), 1754-1764.
28. Greenberg, J.D.; Reed, G.; Kremer, J.M.; Tindall, E.; Kavanaugh, A.; Zheng, C.; Bishai, W.; Hochberg, M.C. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann. Rheum. Dis., 2010, 69(2), 380-386.
29. Dixon, W.G.; Symmons, D.P.; Lunt, M.; Watson, K.D.; Hyrich, K.L.; Silman, A.J., Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum., 2007, 56(9), 2896-2904.
30. Curtis, J.R.; Martin, C.; Saag, K.G.; Patkar, N.M.; Kramer, J.; Shatin, D.; Allison, J.; Braun, M.M. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. Arthritis Rheum., 2007, 57(2), 343-346.
31. Bassetti, S.; Wasmer, S.; Hasler, P.; Vogt, T.; Nogarth, D.; Frei, R.; Widmer, A. F. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment. J. Rheumatol., 2005, 32(11), 2125-2129.
32. Mor, A.; Mitnick, H.J.; Greene, J.B.; Azar, N.; Budnah, R.; Fetto, J. Relapsing oligoarticular septic arthritis during etanercept treatment of rheumatoid arthritis. J. Clin. Rheumatol., 2006, 12(2), 87-89.
33. Netea, M.G.; Radstake, T.; Joosten, L.A.; van der Meer, J.W.; Barrera, P.; Kullberg, B.J. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum., 2003, 48(7), 1853-1857.
34. Pena-Sagredo, J.L.; Farinas, M.C.; Perez-Zafrilla, B.; Cruz-Valenciano, A.; Crespo, M.; Joven-Ibanez, B.; Riera, E.; Manero-Ruiz, F.J.; Chalmeta, I.; Hernandez, M.V.; Rodriguez-Gomez, M.; Maiz, O.; Lopez, R.; Cobo, T.; Pita, J.; Carmona, L.; Gonzalez-Gay, M.A. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy. Clin. Exp. Rheumatol., 2009, 27(6), 920-925.
35. Bergstrom, L.; Yocum, D.E.; Ampel, N.M.; Villanueva, I.; Lisse, J.; Gluck, O.; Tesser, J.; Posever, J.; Miller, M.; Araujo, J.; Kageyama, D.M.; Berry, M.; Karl, L.; Yung, C.M. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum., 2004, 50(6), 1959-1966.
36. Keane, J.; Gershon, S.; Wise, R.P.; Mirabile-Levens, E.; Kasznica, J.; Schwieterman, W.D.; Siegel, J.N.; Braun, M.M., Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N. Engl. J. Med., 2001, 345(15), 1098-10104.
37. Seddik, M.; Melliez, H.; Seguy, D.; Viget, N.; Cortot, A.; Colombel, J.F. Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflamm Bowel Dis, 2005, 11(6), 618-620.
38. Wood, K.L.; Hage, C.A.; Knox, K.S.; Kleiman, M.B.; Sannuti, A.; Day, R.B.; Wheat, L.J.; Twigg, H.L., Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am. J. Respir. Crit. Care Med., 2003, 167(9), 1279-1282.
39. Wallis, R.S.; Broder, M.S.; Wong, J.Y.; Hanson, M.E.; Beenhouwer, D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis., 2004, 38(9), 1261-1265.
40. Slifman, N.R.; Gershon, S.K.; Lee, J.H.; Edwards, E.T.; Braun, M.M. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum., 2003, 48(2), 319-324.
41. Peña-Sagredo, J.L.; Hernández, M.V.; Fernandez-Llanio, N.; Giménez-Ubeda, E.; Muñoz-Fernandez, S.; Ortiz, A.; Gonzalez-Gay, M.A.; Fariñas, M.C., Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin. Exp. Rheumatol., 2008, 26(5), 854-859.
42. Tsiodras, S.; Samonis, G.; Boumpas, D.T.; Kontoyiannis, D.P., Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo. Clin. Proc., 2008, 83(2), 181-194.
43. Allendoerfer, R.; Deepe, G.S., Jr., Blockade of endogenous TNFalpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J. Immunol., 1998, 160(12), 6072-6082.
44. Flynn, J.L.; Goldstein, M.M.; Chan, J.; Triebold, K.J.; Pfeffer, K.; Lowenstein, C.J.; Schreiber, R.; Mak, T.W.; Bloom, B.R., Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity., 1995, 2(6), 561-572.
45. Mohan, V.P.; Scanga, C.A.; Yu, K.; Scott, H.M.; Tanaka, K.E.; Tsang, E.; Tsai, M.M.; Flynn, J.L.; Chan, J. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun., 2001, 69(3), 1847-1855.
46. Bruns, H.; Meinken, C.; Schauenberg, P.; Harter, G.; Kern, P.; Modlin, R.L.; Antoni, C.; Stenger, S. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J. Clin. Invest., 2009, 119(5), 1167-1177.
47. Askling, J.; Fored, C.M.; Brandt, L.; Baecklund, E.; Bertilsson, L.; Coster, L.; Geborek, P.; Jacobsson, L.T.; Lindblad, S.; Lysholm, J.; Rantapaa-Dahlqvist, S.; Saxne, T.; Romanus, V.; Klareskog, L.; Feltelius, N. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum., 2005, 52(7), 1986-1992.
48. Brassard, P.; Lowe, A.M.; Bernatsky, S.; Kezouh, A.; Suissa, S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum., 2009, 61(3), 300-304.
49. Carmona, L.; Hernandez-Garcia, C.; Vadillo, C.; Pato, E.; Balsa, A.; Gonzalez-Alvaro, I.; Belmonte, M.A.; Tena, X.; Sanmarti, R. Increased risk of tuberculosis in patients with rheumatoid arthritis. J. Rheumatol., 2003, 30(7), 1436-1439.
50. Seong, S.S.; Choi, C.B.; Woo, J.H.; Bae, K.W.; Joung, C.L.; Uhm, W.S.; Kim, T.H.; Jun, J.B.; Yoo, D.H.; Lee, J.T.; Bae, S.C. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J. Rheumatol., 2007, 34(4), 706-711.
51. Yamada, T.; Nakajima, A.; Inoue, E.; Tanaka, E.; Hara, M.; Tomatsu, T.; Kamatani, N.; Yamanaka, H. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann. Rheum. Dis., 2006, 65(12), 1661-1663.
52. Ellerin, T.; Rubin, R.H.; Weinblatt, M.E. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum., 2003, 48(11), 3013-3022.
53. Gomez-Reino, J.J.; Carmona, L.; Valverde, V.R.; Mola, E.M.; Montero, M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum., 2003, 48, (8), 2122-2127.
54. Wolfe, F.; Michaud, K.; Anderson, J.; Urbansky, K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum., 2004, 50(2), 372-379.
55. Brassard, P.; Kezouh, A.; Suissa, S. Antirheumatic drugs and the risk of tuberculosis. Clin. Infect. Dis., 2006, 43(6), 717-722.
56. Dixon, W.G.; Hyrich, K.L.; Watson, K.D.; Lunt, M.; Galloway, J.; Ustianowski, A.; Symmons, D.P. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis., 69(3), 522-528.
57. Fonseca, J.E.; Canhao, H.; Silva, C.; Miguel, C.; Mediavilla, M.J.; Teixeira, A.; Castelao, W.; Nero, P.; Bernardes, M.; Bernardo, A.; Mariz, E.; Godinho, F.; Santos, M. J.; Bogas, M.; Oliveira, M.; Saavedra, M.J.; Barcelos, A.; Cruz, M.; Santos, R.A.; Mauricio, L.; Rodrigues, M.; Figueiredo, G.; Quintal, A.; Patto, J.V.; Malcata, A.; da Silva, J.C.; Araujo, D.; Ventura, F.; Branco, J.; Queiroz, M.V. [Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience]. Acta. Reumatol. Port., 2006, 31(3), 247-243.
58. Gomez-Reino, J.J.; Carmona, L.; Angel Descalzo, M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum., 2007, 57(5), 756-761.
59. Tubach, F.; Salmon, D.; Ravaud, P.; Allanore, Y.; Goupille, P.; Breban, M.; Pallot-Prades, B.; Pouplin, S.; Sacchi, A.; Chichemanian, R.M.; Bretagne, S.; Emilie, D.; Lemann, M.; Lortholary, O.; Mariette, X. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum., 2009, 60(7), 1884-1894.
60. Wallis, R.S.; Broder, M.; Wong, J.; Beenhouwer, D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin. Infect. Dis. 2004, 39(8), 1254-125.
61. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003. MMWR. Morb. Mortal Wkly. Rep., 2004, 53(30), 683-686.
62. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax, 2005, 60(10), 800-805.
63. Beglinger, C.; Dudler, J.; Mottet, C.; Nicod, L.; Seibold, F.; Villiger, P.M.; Zellweger, J.P. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med. Wkly., 2007, 137(43-44), 620-622.
64. Carmona, L.; Gomez-Reino, J.J.; Rodriguez-Valverde, V.; Montero, D.; Pascual-Gomez, E.; Mola, E.M.; Carreno, L.; Figueroa, M. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum., 2005, 52(6), 1766-1772.
65. Diel, R.; Hauer, B.; Loddenkemper, R.; Manger, B.; Kruger, K. [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases]. Pneumologie, 2009, 63(6), 329-334.
66. Kavanagh, P.M.; Gilmartin, J.J.; O'Donnell, J.; O'Flanagan, D. Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee. Ir. Med. J., 2008, 101(1), 6-7.
67. Mariette, X.; Salmon, D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann. Rheum. Dis., 2003, 62(8), 791.
68. Smitten, A.L.; Choi, H.K.; Hochberg, M.C.; Suissa, S.; Simon, T.A.; Testa, M.A.; Chan, K.A. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum., 2007, 57(8), 1431-1438.
69. Strangfeld, A.; Listing, J.; Herzer, P.; Liebhaber, A.; Rockwitz, K.; Richter, C.; Zink, A. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA., 2009, 301(7), 737-744.
70. Wolfe, F.; Michaud, K.; Chakravarty, E.F. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and noninflammatory musculoskeletal disorders. Rheumatology (Oxford), 2006, 45(11), 1370-137
71. García-Doval, I. P.-Z. B.; Descalzo, M.A.; Roselló, R.; Hernández, M.V.; Gómez-Reino, J.J.; Carmona, L.; BIOBADASER 2.0 and EMECAR Study Groups, Incidence and risk of herpes zoster and varicella in patients with rheumatic diseases treated with TNF antagonists. nn. Rheum. Dis., 2010, Jun 15. [Epub ahead of print].
72. Ruperto, N.; Lovell, D.J.; Cuttica, R.; Wilkinson, N.; Woo, P.; Espada, G.; Wouters, C.; Silverman, E.D.; Balogh, Z.; Henrickson, M.; Apaz, M.T.; Baildam, E.; Fasth, A.; Gerloni, V.; Lahdenne, P.; Prieur, A.M.; Ravelli, A.; Saurenmann, R.K.; Gamir, M.L.; Wulffraat, N.; Marodi, L.; Petty, R.E.; Joos, R.; Zulian, F.; McCurdy, D.; Myones, B.L.; Nagy, K.; Reuman, P.; Szer, I.; Travers, S.; eutler, A.; Keenan, G.; Clark, J.; Visvanathan, S.; Fasanmade, A.; Raychaudhuri, A.; Mendelsohn, A.; Martini, A.; Giannini, E.H. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum., 2007, 56(9), 3096-3106.
73. Lovell, D.; Reiff, A.; Ilowite, N.; Wallace, C.; Chon, Y.; Lin, S.; Baumgartner, S.; Giannini, E. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum., 2008, 58(5), 1496-1504.
74. Lovell, D.J.; Ruperto, N.; Goodman, S.; Reiff, A.; Jung, L.; Jarosova, K.; Nemcova, D.; Mouy, R.; Sandborg, C.; Bohnsack, J.; Elewaut, D.; Foeldvari, I.; Gerloni, V.; Rovensky, J.; Minden, K.; Vehe, R.K.; Weiner, L.W.; Horneff, G.; Huppertz, H.I.; Olson, N.Y.; Medich, J.R.; Carcereri-De-Prati, R.; McIlraith, M.J.; Giannini, E.H.; Martini, A. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med., 2008, 359(8), 810-820.
75. Gerloni, V.; Pontikaki, I.; Gattinara, M.; Fantini, F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann. Rheum. Dis., 2008, 67(8), 1145-1152.
76. van der Heijde, D.; Schiff, M.H.; Sieper, J.; Kivitz, A.J.; Wong, R. L.; Kupper, H.; Dijkmans, B.A.; Mease, P.J.; Davis, J.C. Jr., Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann. Rheum. Dis., 2009, 68(6), 922-929.
77. Davis, J.C.Jr.; van der Heijde, D.M.; Braun, J.; Dougados, M.; Clegg, D.O.; Kivitz, A.J.; Fleischmann, R.M.; Inman, R.D.; Ni, L.; Lin, S. L.; Tsuji, W.H. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann. Rheum. Dis., 2008, 67(3), 346-352.
78. van der Heijde, D.; Dijkmans, B.; Geusens, P.; Sieper, J.; De-Woody, K.; Williamson, P.; Braun, J. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum., 2005, 52(2), 582-591.
79. Braun, J.; Deodhar, A.; Dijkmans, B.; Geusens, P.; Sieper, J.; Williamson, P.; Xu, W.; Visvanathan, S.; Baker, D.; Goldstein, N.; van der Heijde, D. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum., 2008, 59, (9), 1270-1278.
80. Antoni, C.; Kavanaugh, A.; Kirkham, B.; Tutuncu, Z.; Burmester, G.; Schneider, U.; Furst, D.; Molitor, J.; Keystone, E.; Gladman, D.; Manger, B.; Wassenberg, S.; Weier, R.; Wallace, D.; Weisman, M.; Kalden, J.; Smolen, J. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum., 2005, 52(4), 1227-1236.
81. Antoni, C.; Krueger, G.; de Vlam, K.; Birbara, C.; Beutler, A.; Guzzo, C.; Zhou, B.; Dooley, L.; Kavanaugh, A. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis., 2005, 64(8), 1150-1157.
82. Gladman, D.D.; Mease, P.J.; Ritchlin, C.T.; Choy, E.H.; Sharp, J.T.; Ory, P.A.; Perdok, R.J.; Sasso, E.H. Adalimumab for longterm treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum., 2007, 56(2), 476-488.
83. Mease, P.; Goffe, B.; Metz, J.; VanderStoep, A.; Finck, B.; Burge, D. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet, 2000, 356(9227), 385-390.
84. Mease, P.; Kivitz, A.; Burch, F.; Siegel, E.; Cohen, S.; Ory, P.; Salonen, D.; Rubenstein, J.; Sharp, J.; Tsuji, W. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum., 2004, 50(7), 2264-2272.
85. Mease, P.J.; Gladman, D.D.; Ritchlin, C.T.; Ruderman, E.M.; Steinfeld, S.D.; Choy, E.H.; Sharp, J.T.; Ory, P.A.; Perdok, R.J.; Weinberg, M.A. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a doubleblind, randomized, placebo-controlled trial. Arthritis Rheum., 2005, 52(10), 3279-3289.
86. Mease, P.J.; Ory, P.; Sharp, J.T.; Ritchlin, C.T.; Van den Bosch, F.; Wellborne, F.; Birbara, C.; Thomson, G.T.; Perdok, R.J.; Medich, J.; Wong, R.L.; Gladman, D.D. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann. Rheum. Dis., 2009, 68(5), 702-709.
87. Saad, A.; Symmons, D.; Noyce, P.; Ashcroft, D. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J. Rheumatol., 2008, 35(5), 883-890.
88. Saad, A.; Ashcroft, D.; Watson, K.; Symmons, D.; Noyce, P.; Hyrich, K. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford), 2010, 49(4), 697-705.
89. Kristensen, L.; Gülfe, A.; Saxne, T.; Geborek, P., Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann. Rheum. Dis., 2008, 67(3), 364-369.
90. Carmona, L.D., M.A.; Ruiz-Montesinos, D.; Manero-Ruiz, F.J.; Pérez-Pampin, E.; Gómez-Reino, J.J. on Behalf of the BIOBADASER 2.0 Study Group, Safety and retention rate of offlabel uses of TNF-antagonists in rheumatic conditions: Data from the Spanish registry BIOBADASER 2.0. Rheumatology (Oxford), 2010, Jul 7. [Epub ahead of print].
91. Haroon, N.; Inman, R.D. Infectious complications of biological therapy. Curr. Opin. Rheumatol., 2009, 21(4), 397-403.